Efficacy and Resistance in De Novo Combination Lamivudine and Adefovir Dipivoxil Therapy Versus Entecavir Monotherapy for the Treatment-naive Patients with Chronic Hepatitis B: a Meta-analysis

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2014 Mar 29

PMID 24673792

Citations 17

Authors

Fen Liu

Xiwei Wang

Fang Wei

Huaidong Hu

Dazhi Zhang

Peng Hu

Hong Ren

Affiliations

Soon will be listed here.

Abstract

Background: Currently, there is no consensus on the efficacy and resistance of de novo combination therapy versus monotherapy for treatment naive patients of chronic hepatitis B (CHB).

Objectives: The aim of this study was to evaluate the effectiveness and resistance of de novo combination of lamivudine (LAM) and adefovir dipivoxil (ADV) compared with entecavir (ETV) monotherapy for nucleos(t)ide-naive patients with CHB.

Study Design: Publications on the effectiveness and resistance of LAM plus ADV versus ETV monotherapy for nucleos(t)ide-naive patients with CHB were identified by a search of PubMed, Embase, the Cochrane Library, Web of science, OVID, and CBM (Chinese Biological Medical Literature) until May 1, 2013. Biochemical response, hepatitis B e antigen seroconversion, and viroligic response were extracted and combined to obtain an integrated result. Viral resistance and safety were reviewed.

Results: Five eligible studies (328 patients in total) were included in the analysis. LAM plus ADV combination therapy produced more rapid HBV DNA reduction rate at 12 weeks than that of ETV monotherapy. At 48 weeks, the combination group had superior viroligic response rates compared with ETV group (90.0% vs. 78.9%, P=0.01). The difference in the ALT normalization and HBeAg seroconversion rates was not found. At week 96, LAM + ADV was more effective than ETV in ALT normalization [RR = 1. 11, 95% CI (1.02, 1.21), P =0.01] and HBeAg seroconversion [RR = 2.00, 95% CI (1.26, 3.18, P=0.003)], and no significant difference was found in the virologic response (P =0.23). No viral resistance occurred in combination therapy and six patients in ETV group were experienced with viral breakthrough. Both groups were well tolerated.

Conclusion: The de novo LAM plus ADV combination therapy for treatment-naïve patients with CHB was greater than ETV monotherapy in both biochemical response and HBeAg seroconversion rate up to 96 weeks. The rate of emergence of viral resistance in the combination group was less than that in the ETV monotherapy.

Citing Articles

Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: A network meta-analysis.

Zhao Y, Song Y, Zhang H, Qu T, Axinbai M, Yang Y Front Oncol. 2023; 12:1050714.

PMID: 36727050 PMC: 9885183. DOI: 10.3389/fonc.2022.1050714.

Comparing the efficacy and safety of tenofovir and adefovir or combined drug treatment for the treatment of chronic hepatitis B infection: a systematic review and meta-analysis.

Bi Z, Wang L, Hou H, Lu M, Wang W, Li Z Ann Transl Med. 2022; 10(18):1016.

PMID: 36267714 PMC: 9577806. DOI: 10.21037/atm-22-3747.

Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy.

Huang M, Zhong J, Lu C, Deng F, Li L, Nong Y Pharmgenomics Pers Med. 2019; 12:297-303.

PMID: 31695474 PMC: 6814354. DOI: 10.2147/PGPM.S224256.

An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes.

Furutani Y, Toguchi M, Shiozaki-Sato Y, Qin X, Ebisui E, Higuchi S PLoS One. 2019; 14(6):e0216139.

PMID: 31188831 PMC: 6561549. DOI: 10.1371/journal.pone.0216139.

Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study.

Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G Infect Drug Resist. 2019; 12:745-757.

PMID: 31015765 PMC: 6448536. DOI: 10.2147/IDR.S185120.

References

Yao G, Zhu M, Cui Z, Wang B, Yao J, Zeng M . A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis. 2009; 10(2):131-7. DOI: 10.1111/j.1751-2980.2009.00375.x. View

Nagasaki F, Niitsuma H, Ueno Y, Inoue J, Kogure T, Fukushima K . The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus. Tohoku J Exp Med. 2007; 213(2):181-6. DOI: 10.1620/tjem.213.181. View

Heo N, Lim Y, Lee H, Chung Y, Lee Y, Suh D . Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010; 53(3):449-54. DOI: 10.1016/j.jhep.2010.03.020. View

Fung J, Lai C, Seto W, Yuen M . Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011; 66(12):2715-25. DOI: 10.1093/jac/dkr388. View

Neumann-Fraune M, Beggel B, Pfister H, Kaiser R, Verheyen J . High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates. J Med Virol. 2013; 85(5):775-9. DOI: 10.1002/jmv.23530. View

Tenney D, Levine S, Rose R, Walsh A, Weinheimer S, Discotto L . Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004; 48(9):3498-507. PMC: 514758. DOI: 10.1128/AAC.48.9.3498-3507.2004. View

Kim D, Chang H, Lim S, Kim S, Park J, Kim J . Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B. Gut Liver. 2013; 7(3):329-34. PMC: 3661966. DOI: 10.5009/gnl.2013.7.3.329. View

Wolters L, Niesters H, de Man R . Nucleoside analogues for chronic hepatitis B. Eur J Gastroenterol Hepatol. 2001; 13(12):1499-506. DOI: 10.1097/00042737-200112000-00016. View

Tenney D, Rose R, Baldick C, Pokornowski K, Eggers B, Fang J . Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009; 49(5):1503-14. DOI: 10.1002/hep.22841. View

10.

Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C . Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 2008; 48(5):747-55. DOI: 10.1016/j.jhep.2008.01.027. View

11.

Dienstag J . Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 2009; 49(5 Suppl):S112-21. DOI: 10.1002/hep.22920. View

12.

Yu J, Shi J, Wu J, Li X, Guo J, Xun Y . [Efficacy and safety of lamivudine plus adefovir combination therapy and entecavir monotherapy for chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi. 2011; 19(2):88-92. DOI: 10.3760/cma.j.issn.1007-3418.2011.02.004. View

13.

Patterson S, Angus P . Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant. 2009; 14(3):225-30. DOI: 10.1097/MOT.0b013e32832b1f32. View

14.

Thornton A, Lee P . Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol. 2000; 53(2):207-16. DOI: 10.1016/s0895-4356(99)00161-4. View

15.

Liaw Y, Kao J, Piratvisuth T, Chan H, Chien R, Liu C . Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2015; 6(3):531-61. DOI: 10.1007/s12072-012-9365-4. View

16.

Lu H, Zhuang L, Yu Y, Si C . Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients. J Viral Hepat. 2010; 17 Suppl 1:59-65. DOI: 10.1111/j.1365-2893.2010.01272.x. View

17.

Wu B, Shen J, Cheng H . Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China. BMC Health Serv Res. 2012; 12:385. PMC: 3511237. DOI: 10.1186/1472-6963-12-385. View

18.

Kim S, Cho S, Kim S, Hong S, Cheong J . Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy. J Med Virol. 2012; 85(1):55-64. DOI: 10.1002/jmv.23440. View

19.

Rapti I, Dimou E, Mitsoula P, Hadziyannis S . Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007; 45(2):307-13. DOI: 10.1002/hep.21534. View

20.

Kim H, Park J, Park D, Cho Y, Sohn C, Jeon W . Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol. 2010; 25(8):1374-80. DOI: 10.1111/j.1440-1746.2010.06381.x. View